PRQR
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.09 · operating margin -276% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 800 000 titres (~1 342 385,00 $ US)
- Insiders
- de Boer Daniel AntonFilius Bart
- Total bought
-
$1,342,385
Avg buy (VWAP, 90d window) $1.68 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-07-31
- Last synced
-
2026-08-06 10:27:36
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-31 | de Boer Daniel Anton | Buy | 200,000 | $1.77 | $353,960 | Form 4 |
| 2026-07-17 | Filius Bart | Buy | 150,000 | $1.72 | $257,925 | Form 4 |
| 2026-07-09 | de Boer Daniel Anton | Buy | 150,000 | $1.74 | $261,000 | Form 4 |
| 2026-07-07 | de Boer Daniel Anton | Buy | 150,000 | $1.59 | $238,500 | Form 4 |
| 2026-06-26 | Filius Bart | Buy | 150,000 | $1.54 | $231,000 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-26
PRQR presents a meaningful insider cluster buy signal (800k shares, ~$1.34M) following positive Phase 1 data for AX-0810, which provides genuine near-term catalytic interest; however, the underlying financial health is…
The first sentence of the analysis written for PRQR on 2026-08-26 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -259.4% | -142.2% | -408.5% | -1641.1% | -4290.4% | |
| Ebitda Margin | -242.4% | -127.6% | -369.9% | -1571.0% | -4116.0% | |
| Operating Profit Margin | -275.9% | -161.2% | -489.1% | -1813.0% | -4285.4% | |
| Pretax Profit Margin | -265.1% | -147.9% | -427.0% | -1783.8% | -4545.5% | |
| Continuous Operations Profit Margin | -265.2% | -146.9% | -425.8% | -1786.4% | -4554.2% | |
| Net Profit Margin | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | |
| Bottom Line Profit Margin | -265.2% | -146.9% | -431.7% | -1792.5% | -4549.8% | |
| Current Ratio | 3.086 | 3.955 | 3.537 | 7.359 | 6.939 | |
| Quick Ratio | 3.086 | 3.955 | 3.537 | 7.359 | 6.939 | |
| Solvency Ratio | -0.599 | -0.315 | -0.240 | -0.592 | -0.606 | |
| Cash Ratio | 2.849 | 3.841 | 3.477 | 4.516 | 6.795 | |
| Price To Earnings Ratio | -4.524 | -7.527 | -5.118 | -3.797 | -7.337 | |
| Price To Earnings Growth Ratio | -0.385 | 2.634 | 0.083 | 0.729 | -2.275 | |
| Forward Price To Earnings Growth Ratio | -0.385 | 2.634 | 0.083 | 0.729 | -2.275 | |
| Price To Earnings Diluted Ratio | -4.524 | -7.527 | -5.118 | -3.797 | -7.337 | |
| Price To Earnings Diluted Growth Ratio | -0.385 | 2.634 | 0.083 | 0.729 | -2.275 | |
| Price To Book Ratio | 3.669 | 2.360 | 3.174 | 3.691 | 3.972 | |
| Price To Sales Ratio | 11.853 | 11.055 | 22.278 | 68.879 | 338.653 | |
| Price To Free Cash Flow Ratio | -3.504 | -5.527 | 7.192 | -3.577 | -17.063 | |
| Price To Operating Cash Flow Ratio | -3.571 | -5.743 | 6.735 | -3.613 | -17.380 | |
| Debt To Assets Ratio | 0.124 | 0.103 | 0.143 | 0.128 | 0.288 | |
| Debt To Equity Ratio | 0.283 | 0.194 | 0.477 | 0.328 | 0.530 | |
| Debt To Capital Ratio | 0.221 | 0.163 | 0.323 | 0.247 | 0.347 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.094 | 0.060 | 0.257 | |
| Financial Leverage Ratio | 2.284 | 1.897 | 3.331 | 2.555 | 1.841 | |
| Working Capital Turnover Ratio | 0.167 | 0.179 | 0.057 | 0.024 | 0.011 | |
| Operating Cash Flow Ratio | -1.564 | -0.936 | 0.570 | -3.264 | -0.943 | |
| Operating Cash Flow Sales Ratio | -3.319 | -1.925 | 3.308 | -19.062 | -19.485 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | 1.039 | 0.936 | 1.010 | 1.019 | |
| Debt Service Coverage Ratio | -6.981 | -4.228 | -8.044 | -7.415 | -6.735 | |
| Interest Coverage Ratio | -48.655 | -28.293 | -26.483 | -12.709 | -16.802 | |
| Short Term Operating Cash Flow Coverage Ratio | -11.415 | -7.943 | 12.086 | -27.403 | -5.452 | |
| Operating Cash Flow Coverage Ratio | -3.626 | -2.114 | 0.988 | -3.118 | -0.431 | |
| Capital Expenditure Coverage Ratio | -51.756 | -25.665 | 15.717 | -96.763 | -53.744 | |
| Dividend Paid And Capex Coverage Ratio | -51.756 | -25.665 | 15.717 | -96.763 | -53.744 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.773 | -3.184 | -1.475 | -3.095 | -5.914 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 83.0% | ▼-17.0% | ▼-13.6% |
| Ebit Margin | -259.4% | ▼-117.2% | ▲1088.9% |
| Ebitda Margin | -242.4% | ▼-114.8% | ▲1043.0% |
| Operating Profit Margin | -275.9% | ▼-114.7% | ▲1129.0% |
| Pretax Profit Margin | -265.1% | ▼-117.2% | ▲1168.8% |
| Continuous Operations Profit Margin | -265.2% | ▼-118.3% | ▲1170.5% |
| Net Profit Margin | -265.2% | ▼-118.3% | ▲1172.0% |
| Bottom Line Profit Margin | -265.2% | ▼-118.3% | ▲1172.0% |
| Current Ratio | 3.086 | ▼-0.868 | ▼-1.889 |
| Quick Ratio | 3.086 | ▼-0.868 | ▼-1.889 |
| Solvency Ratio | -0.599 | ▼-0.284 | ▼-0.128 |
| Cash Ratio | 2.849 | ▼-0.992 | ▼-1.447 |
| Price To Earnings Ratio | -4.524 | ▲3.002 | ▲1.137 |
| Price To Earnings Growth Ratio | -0.385 | ▼-3.019 | ▼-0.542 |
| Forward Price To Earnings Growth Ratio | -0.385 | ▼-3.019 | ▼-0.542 |
| Price To Earnings Diluted Ratio | -4.524 | ▲3.002 | ▲1.137 |
| Price To Earnings Diluted Growth Ratio | -0.385 | ▼-3.019 | ▼-0.542 |
| Price To Book Ratio | 3.669 | ▲1.310 | ▲0.296 |
| Price To Sales Ratio | 11.853 | ▲0.798 | ▼-78.690 |
| Price To Free Cash Flow Ratio | -3.504 | ▲2.024 | ▲0.992 |
| Price To Operating Cash Flow Ratio | -3.571 | ▲2.171 | ▲1.143 |
| Debt To Assets Ratio | 0.124 | ▲0.022 | ▼-0.033 |
| Debt To Equity Ratio | 0.283 | ▲0.089 | ▼-0.079 |
| Debt To Capital Ratio | 0.221 | ▲0.058 | ▼-0.039 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.082 |
| Financial Leverage Ratio | 2.284 | ▲0.387 | ▼-0.098 |
| Working Capital Turnover Ratio | 0.167 | ▼-0.012 | ▲0.080 |
| Operating Cash Flow Ratio | -1.564 | ▼-0.628 | ▼-0.337 |
| Operating Cash Flow Sales Ratio | -3.319 | ▼-1.394 | ▲4.778 |
| Free Cash Flow Operating Cash Flow Ratio | 1.019 | ▼-0.020 | ▲0.015 |
| Debt Service Coverage Ratio | -6.981 | ▼-2.753 | ▼-0.300 |
| Interest Coverage Ratio | -48.655 | ▼-20.362 | ▼-22.067 |
| Short Term Operating Cash Flow Coverage Ratio | -11.415 | ▼-3.473 | ▼-3.390 |
| Operating Cash Flow Coverage Ratio | -3.626 | ▼-1.512 | ▼-1.966 |
| Capital Expenditure Coverage Ratio | -51.756 | ▼-26.091 | ▼-9.314 |
| Dividend Paid And Capex Coverage Ratio | -51.756 | ▼-26.091 | ▼-9.314 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.773 | ▲0.411 | ▲0.515 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $181.1M | $209.0M | $145.1M | $247.6M | $452.1M | |
| Enterprise value | $102.7M | $76.8M | $35.5M | $174.7M | $324.9M | |
| EV / Sales | 6.72x | 4.06x | 5.46x | 48.62x | 243.41x | |
| EV / Op. cash flow | -2.02x | -2.11x | 1.65x | -2.55x | -12.49x | |
| EV / Free cash flow | -1.99x | -2.03x | 1.76x | -2.52x | -12.26x | |
| EV / EBITDA | -2.77x | -3.18x | -1.48x | -3.10x | -5.91x | |
| Net debt / EBITDA | 2.12x | 5.48x | 4.55x | 1.29x | 2.31x | |
| Current ratio | 3.09x | 3.96x | 3.54x | 7.36x | 6.94x | |
| Income quality | 1.25x | 1.31x | -0.78x | 1.07x | 0.43x | |
| Graham net-net | $0 | $1 | $0 | $0 | $1 | |
| Tax burden | 100.0% | 99.3% | 101.1% | 100.5% | 100.1% | |
| Interest burden | 102.2% | 104.0% | 104.5% | 108.7% | 105.9% | |
| Working capital | $67.7M | $114.9M | $95.9M | $133.5M | $163.9M | |
| Invested capital | $80.3M | $129.1M | $114.5M | $149.7M | $181.4M | |
| Return on assets | -36.0% | -16.5% | -18.5% | -37.6% | -29.0% | |
| Operating ROA | -30.0% | -19.0% | -19.7% | -34.2% | -34.6% | |
| Return on tangible assets | -36.0% | -16.5% | -18.5% | -37.6% | -29.0% | |
| Return on equity | -82.1% | -31.3% | -61.5% | -96.1% | -53.4% | |
| Return on invested capital | -49.8% | -22.4% | -27.3% | -42.3% | -30.4% | |
| Return on capital employed | -52.5% | -23.6% | -27.8% | -43.3% | -31.4% | |
| Earnings yield | -22.4% | -13.3% | -19.4% | -26.0% | -13.4% | |
| Free cash flow yield | -28.5% | -18.1% | 13.9% | -28.0% | -5.9% | |
| Capex / Op. cash flow | -1.9% | -3.9% | 6.4% | -1.0% | -1.9% | |
| Capex / Depreciation | 37.7% | 51.4% | 54.6% | 28.1% | 20.8% | |
| Capex / Sales | 6.4% | 7.5% | 21.0% | 19.7% | 36.3% | |
| SG&A / Sales | 98.6% | 72.3% | 249.2% | 518.9% | 1301.0% | |
| R&D / Sales | 266.5% | 192.3% | 386.1% | 1415.3% | 3162.5% | |
| Stock comp / Sales | 0.0% | 13.5% | 47.7% | 79.8% | 465.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 121d | 39d | 78d | 5713d | 225d | |
| Days payables outstanding | 42d | 0d | 0d | 0d | 0d | |
| Operating cycle | 121d | 39d | 78d | 5713d | 225d | |
| Cash conversion cycle | 80d | 39d | 78d | 5713d | 225d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-13.3%EV / Sales ▲+65.5%EV / EBITDA ▲+12.9%EV / Op. cash flow ▲+0.085Earnings yield ▼-0.091
Profitability
Return on equity ▼-0.508Return on assets ▼-0.194Return on invested capital ▼-0.274Return on capital employed ▼-0.289Operating ROA ▼-0.110Income quality ▼-0.059Tax burden ▲+0.007
Efficiency
Days sales outstanding ▲+82.318Days payables outstanding n/aOperating cycle ▲+82.318Cash conversion cycle ▲+40.442Capex / Sales ▼-0.011R&D / Sales ▲+0.742
Balance-sheet strength
Current ratio ▼-0.868Net debt / EBITDA ▼-3.364Working capital ▼-47286807.000Invested capital ▼-48775183.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-59.9%EV / Sales ▼-97.2%EV / EBITDA ▲+53.1%EV / Op. cash flow ▲+10.467Earnings yield ▼-0.089
Profitability
Return on equity ▼-0.287Return on assets ▼-0.070Return on invested capital ▼-0.194Return on capital employed ▼-0.211Operating ROA ▲+0.046Income quality ▲+0.824Tax burden ▼-0.001
Efficiency
Days sales outstanding ▼-103.561Days payables outstanding n/aOperating cycle ▼-103.561Cash conversion cycle ▼-145.437Capex / Sales ▼-0.298R&D / Sales ▼-28.960
Balance-sheet strength
Current ratio ▼-3.852Net debt / EBITDA ▼-0.198Working capital ▼-96230807.000Invested capital ▼-101073183.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-04 ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of “Moderate Buy” from Analysts ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the
- 2026-07-04 ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810''s Phase 1 target engagement data. PRQR differentiates itself by prioritizing NTCP modulation in rare pediatric liver disease (biliary atresia), aiming for a faster, cleaner clinical validation path than competitors. Recent financings, including a $50M direct offering and Eli Lilly''s $9.2M investment, extend PRQR''s cash runway to mid-2027, supporting multiple clinical programs.
- 2026-06-25 ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR.
- 2026-06-25 ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change (6 mg/kg) in total bile acids in serum, exceeding the 2-fold threshold identified by the Company as a meaningful indicator of NTCP modulation, along with concordant readouts of bile acid profile and TUDCA markersFavorable safety and tolerability profile observed with AX-0810 to date, with no serious adverse events or pruritus reported; pharmacokinetic findings to date support sustained target engagement, including a half-life of eight weeksThe NTCP biomarker findings support advancement of next-generation candidate AX-0811 and future clinical studies in biliary atresia LEIDEN, Netherlands and CAMBRIDGE, Mass.
- 2026-06-25 ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the Company''s first investigational Axiomer RNA editing oligonucleotide (EON), in healthy volunteers.
- 2026-05-12 ProQR Announces First Quarter 2026 Operating and Financial Results AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
- 2026-05-11 ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
- 2026-05-07 Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline ProQR (PRQR) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.